日本重症监护病房严重脓毒症与脓毒性休克患者感染部位及死亡率的差异
该研究为多中心前瞻性队列研究的二次分析,纳入2016年1月至2017年3月日本59个ICU收治的1184例成人(≥16岁)严重脓毒症和脓毒性休克患者,按脓毒症-2标准诊断。感染部位由接诊医生判定,包括肺、腹腔、尿路、软组织、血流、中枢神经系统(CNS)及未分化感染,主要终点为院内死亡率。最常见感染部位为肺(31.0%),其次为腹腔(26.3%)、尿路(18.4%)和软组织(10.9%);脓毒性休克在腹腔感染(72.2%)和尿路感染(70.2%)中更常见。汇总院内死亡率为23.4%(范围11.9%[尿路感染]至47.6%[CNS感染]);调整后院内死亡率从无休克的尿路感染7.7%(95%CI -0.3至15.8)至有休克的CNS感染58.3%(95%CI 21.0至95.7)。腹腔和尿路感染与低于肺炎的院内死亡率统计学相关;CNS感染在logistic回归模型中与高于肺炎的院内死亡率统计学相关,但在广义估计方程模型中无此关联。
要点
- 日本59个ICU的1184例严重脓毒症/脓毒性休克成人中,最常见感染部位为肺(31.0%),其次为腹腔(26.3%)、尿路(18.4%)和软组织(10.9%)。
- 脓毒性休克在腹腔感染(72.2%)和尿路感染(70.2%)中更常见。
- 汇总院内死亡率为23.4%,范围从尿路感染的11.9%至CNS感染的47.6%。
- 调整后院内死亡率从无休克的尿路感染7.7%(95%CI -0.3至15.8)至有休克的CNS感染58.3%(95%CI 21.0至95.7)。
- 腹腔和尿路感染与低于肺炎的院内死亡率统计学相关;CNS感染在logistic回归模型中与高于肺炎的院内死亡率统计学相关,但在广义估计方程模型中无此关联。
适用人群与场景
- 日本59个ICU于2016年1月至2017年3月收治的1184例成人(≥16岁)严重脓毒症和脓毒性休克患者,按脓毒症-2标准诊断。
诊断标准与关键阈值
- 严重脓毒症和脓毒性休克按脓毒症-2标准诊断。
- 感染部位由接诊医生在到达时判定,包括肺、腹腔、尿路、软组织、血流、中枢神经系统(CNS)及未分化感染。
研究设计与关键结果
- 研究类型:多中心前瞻性队列研究的二次分析,纳入59个ICU,1184例成人(≥16岁)严重脓毒症和脓毒性休克患者,按脓毒症-2标准诊断。
- 最常见感染部位:肺31.0%,腹腔26.3%,尿路18.4%,软组织10.9%。
- 脓毒性休克发生率:腹腔感染72.2%,尿路感染70.2%,高于其他部位。
- 院内死亡率:汇总样本23.4%,范围11.9%(尿路感染)至47.6%(CNS感染)。
- 调整后院内死亡率:无休克的尿路感染7.7%(95%CI -0.3至15.8),有休克的CNS感染58.3%(95%CI 21.0至95.7),采用广义估计方程模型。
- 腹腔和尿路感染与低于肺炎的院内死亡率统计学相关;CNS感染在logistic回归模型中与高于肺炎的院内死亡率统计学相关,但在广义估计方程模型中无此关联。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Accurate and early identification of infection sites might help to drive crucial decisions regarding the treatment of sepsis. We aimed to determine the clinical and etiological features of infection according to sites among patients with severe sepsis in Japan.
METHODS: This secondary analysis of a multicenter, prospective cohort study included 59 intensive care units (ICU) and proceeded between January 2016 and March 2017. The study cohort comprised 1184 adults (≥ 16 years) who were admitted to an ICU with severe sepsis and septic shock diagnosed according to the sepsis-2 criteria. Sites of infection diagnosed by physicians in charge at the time of arrival comprised the lung, abdomen, urinary tract, soft tissue, bloodstream, central nervous system (CNS), and undifferentiated infections. The primary outcome was in-hospital mortality.
RESULTS: The most common sites of infection were the lungs (31.0%), followed by intra-abdominal sites (26.3%), the urinary tract (18.4%), and soft tissue (10.9%). The characteristics of the patients with severe sepsis across seven major suspected infection sites were heterogeneous. Septic shock was more frequent among patients with intra-abdominal (72.2%) and urinary tract (70.2%) infections than other sites. The in-hospital mortality rate due to severe sepsis and septic shock of a pooled sample was 23.4% (range, 11.9% [urinary tract infection] to 47.6% [CNS infection]). After adjusting for clinical background, sepsis severity, and stratification according to the presence or absence of shock, variations in hospital mortality across seven major sites of infection remained essentially unchanged from those for crude in-hospital mortality; adjusted in-hospital mortality rates ranged from 7.7% (95%CI, - 0.3 to 15.8) for urinary tract infection without shock to 58.3% (95%CI, 21.0-95.7) for CNS infection with shock in a generalized estimating equation model. Intra-abdominal and urinary tract infections were statistically associated with less in-hospital mortality than pneumonia. Infections of the CNS were statistically associated with higher in-hospital mortality rates than pneumonia in a logistic regression model, but not in the generalized estimating equation model.
CONCLUSIONS: In-hospital mortality and clinical features of patients with severe sepsis and septic shock were heterogeneous according to sites of infection.
参考来源
- Abe T, Ogura H, Kushimoto S, et al. Variations in infection sites and mortality rates among patients in intensive care units with severe sepsis and septic shock in Japan. J Intensive Care. 2019. PMID: 31073407. doi:10.1186/s40560-019-0383-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。